Back

The impact of the WCD for patients who choose to wear it.

18 March 2019 (13:20 - 13:35)
Organised by:
Congress Presentation Part of: Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death ARRHYTHMIAS AND DEVICE THERAPY EHRA Premium Access EHRA 2019

About the speaker

Photo
Professor Daniel Scherr

Medical University of Graz, Graz (Austria)

4 More presentations in this session

Presentation thumbnail
Introduction - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.
Doctor G. Botto (Garbagnate Milanese, IT)
Slides Video
Presentation thumbnail
Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?
Doctor S. Reif (Munich, DE)
Slides Video
Presentation thumbnail
Strategies for screening and identifying which patients to protect with the WCD.
Professor J. Ehrlich (Wiesbaden, DE)
Slides Video
Presentation thumbnail
Panel discussion and summary - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.
Doctor O. Piot (Saint-Denis, FR)
Slides Video

Access the full session

Session thumbnail
Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death

The Event

Event poster

EHRA 2019

18 March 2019 13:20 CET
You may be interested in
thumbnail
Congress Session
Ventricular storm (2)
thumbnail
Congress Session
How to treat arrhythmias in heart failure
thumbnail
Congress Session
Novel arrhythmia treatments

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources